Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"sPD-1"”.

  1. Cirkuliuojančių prostatos vėžio imuninių veiksnių prognostinis vaidmuo /

    … one of the most common malignancies worldwide. sPD-1 and sPD-L1 molecules are poorly characterised in prostate cancer, but these molecules may provide new insights into disease progression and prognosis. The main aim of this study was to evaluate the prognostic value of circulating sPD-1, sPD-L1 …

    vilnius Repository record for Cirkuliuojančių prostatos vėžio imuninių veiksnių prognostinis vaidmuo / (opens in a new tab)

  2. Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo /

    … in the treatment of prostate cancer. Soluble sPD-(L)1 factors and chemotherapy drugs might possibly dictate atezolizumab effectiveness and an outcome of prostate cancer treatment. The main aim of this thesis is to describe sPD-(L)1 and chemotherapy drugs impact on atezolizumab effectiveness. …

    vilnius Repository record for Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo / (opens in a new tab)

  3. Barriers to Transit-Oriented Development in Mature Communities: An assessment of South Point Douglas, Winnipeg

    … be on the South Point Douglas Neighbourhood (SPD), an economically disadvantaged, mature community and an important area for the City’s development. TOD is a type of development adjacent to rapid transit stations with the goal of promoting a certain level of density and mixed-uses such as …

    manitoba Repository record for Barriers to Transit-Oriented Development in Mature Communities: An assessment of South Point Douglas, Winnipeg (opens in a new tab)

  4. Investigating biomarkers of response to anti-PD1 therapy in Hepatocellular Carcinoma

    … differences in soluble (s)BTLA, sCD27, sCD28, sPD-L1 at baseline between responders and non-responders in 240mg Nivolumab treated patients and differences in sMICB levels at baseline between R and NR in uninfected HCC patients. Longitudinally, differences in sCR concentration are observed in …

    kings Repository record for Investigating biomarkers of response to anti-PD1 therapy in Hepatocellular Carcinoma (opens in a new tab) Embargoed until 2028-06-01